Baxter aims to divide and conquer


US drugmaker Baxter International is spinning off its biopharmaceuticals business to create two independent companies.

The biopharma unit will include Baxter’s existing plasma- and recombinant protein-based drugs for haemophilia, along with treatments for other blood-related conditions. The company stated that it will look to add to its pipeline of treatments and diagnostics for bleeding disorders through collaborations and acquisitions.

The remaining ‘medical products’ outfit includes Baxter’s dialysis equipment, as well as intravenous drug delivery systems, anaesthetics and surgical equipment. That business will aim to grow by increasing its geographical reach and streamlining costs.


Related Content

Baxter to pay $4bn for dialysis firm

6 December 2012 Business

news image

Gambro makes products for hemodialysis and continuous renal replacement therapy

10 years ago - Alain Baxter

1 May 2012 Flashback

news image

British Olympic skier Alain Baxter had his bronze medal taken away after a post-race drug test showed traces of methamphetami...

Most Read

Wind-powered lighting is almost a breeze

13 August 2014 Research

news image

Mechanoluminescent materials seen in a new light

History of King Richard III written in his teeth

18 August 2014 Research

news image

Chemical analysis of isotope signatures in monarch's remains provide insight into his life

Most Commented

Why can we walk on custard?

12 July 2012 Research

news image

Scientists take a closer look at how shear-thickening fluids respond to impacts

Photon pinball identifies chemicals from afar

13 August 2014 Research

news image

Samples turned into random Raman lasers beam their secrets from over a kilometre away